Xiao-Qing-Long Tang Prevents Cardiomyocyte Hypertrophy, Fibrosis, and the Development of Heart Failure with Preserved Ejection Faction in Rats by Modulating the Composition of the Gut Microbiota.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
03
2019
revised:
28
05
2019
accepted:
25
06
2019
entrez:
10
8
2019
pubmed:
10
8
2019
medline:
16
1
2020
Statut:
epublish
Résumé
Changes in the gut microbiota are associated with cardiovascular disease progression. Xiao-Qing-Long Tang (XQLT), a traditional herbal formula, has an anti-inflammatory effect and regulates the steady state of the immune system, which is also associated with the progression of heart failure with preserved ejection faction (HFpEF). In this study, we investigated whether XQLT could contribute to prevent the development of HFpEF and whether the modulation of the gut microbiota by this herbal formula could be involved in such effect. The gut microbiota, SCFAs, the histology/function of the heart, and systolic blood pressure were examined to evaluate the effect of XQLT on the gut microbiota and the progression of HFpEF after oral administration of XQLT to model rats. Furthermore, we evaluated, through fecal microbiota transplantation experiments, whether the favorable effects of XQLT could be mediated by the gut microbiota. Oral administration of XQLT contributed to the reduction of elevated blood pressure, inflammation, and compensatory hypertrophy, features that are associated with the progression of HFpEF. The gut microbiota composition, SCFA levels, and intestinal mucosal histology were improved after treatment with XQLT. Moreover, fecal transfer from XQLT-treated rats was sufficient to prevent the progression of HFpEF. These data suggested that XQLT prevented the development of HFpEF in model rats by regulating the composition of the gut microbiota.
Sections du résumé
BACKGROUND
BACKGROUND
Changes in the gut microbiota are associated with cardiovascular disease progression. Xiao-Qing-Long Tang (XQLT), a traditional herbal formula, has an anti-inflammatory effect and regulates the steady state of the immune system, which is also associated with the progression of heart failure with preserved ejection faction (HFpEF). In this study, we investigated whether XQLT could contribute to prevent the development of HFpEF and whether the modulation of the gut microbiota by this herbal formula could be involved in such effect.
METHODS
METHODS
The gut microbiota, SCFAs, the histology/function of the heart, and systolic blood pressure were examined to evaluate the effect of XQLT on the gut microbiota and the progression of HFpEF after oral administration of XQLT to model rats. Furthermore, we evaluated, through fecal microbiota transplantation experiments, whether the favorable effects of XQLT could be mediated by the gut microbiota.
RESULTS
RESULTS
Oral administration of XQLT contributed to the reduction of elevated blood pressure, inflammation, and compensatory hypertrophy, features that are associated with the progression of HFpEF. The gut microbiota composition, SCFA levels, and intestinal mucosal histology were improved after treatment with XQLT. Moreover, fecal transfer from XQLT-treated rats was sufficient to prevent the progression of HFpEF.
CONCLUSIONS
CONCLUSIONS
These data suggested that XQLT prevented the development of HFpEF in model rats by regulating the composition of the gut microbiota.
Identifiants
pubmed: 31396536
doi: 10.1155/2019/9637479
pmc: PMC6668541
doi:
Substances chimiques
Drugs, Chinese Herbal
0
sho-seiryu-to
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9637479Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Phytomedicine. 2001 Sep;8(5):338-47
pubmed: 11695876
N Engl J Med. 2006 Jul 20;355(3):251-9
pubmed: 16855265
Subcell Biochem. 2010;53:3-25
pubmed: 20593260
Nutr Res Rev. 2010 Dec;23(2):366-84
pubmed: 20937167
Circ Heart Fail. 2011 Jan;4(1):44-52
pubmed: 21075869
J Am Coll Cardiol. 2011 Feb 22;57(8):977-85
pubmed: 21329845
Eur Heart J. 2012 Jul;33(14):1787-847
pubmed: 22611136
Ann N Y Acad Sci. 2012 Jul;1258:52-9
pubmed: 22731715
Cell Host Microbe. 2012 Aug 16;12(2):139-52
pubmed: 22863420
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Eur Heart J. 2013 May;34(19):1424-31
pubmed: 23470495
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Nat Methods. 2013 Oct;10(10):996-8
pubmed: 23955772
Circ Res. 2013 Aug 30;113(6):646-59
pubmed: 23989710
Heart Fail Rev. 2014 Sep;19(5):681-94
pubmed: 24005868
Blood Purif. 2014;37 Suppl 1:1
pubmed: 24457486
Circulation. 2015 Apr 7;131(14):1247-59
pubmed: 25637629
Int J Cardiol. 2015;189:259-63
pubmed: 25897922
Trends Biotechnol. 2015 Sep;33(9):496-503
pubmed: 26210164
Curr Cardiol Rep. 2015 Dec;17(12):120
pubmed: 26497040
Nutrients. 2016 Feb 29;8(3):126
pubmed: 26938554
Biochem Pharmacol. 2016 Oct 15;118:59-67
pubmed: 27553476
Environ Microbiol Rep. 2016 Dec;8(6):1024-1037
pubmed: 27717172
Circulation. 2017 Mar 7;135(10):964-977
pubmed: 27927713
N Engl J Med. 2016 Nov 10;375(19):1868-1877
pubmed: 27959663
Front Immunol. 2017 Jan 23;8:23
pubmed: 28167944
Sci Rep. 2017 May 8;7(1):1529
pubmed: 28484247
Int J Environ Res Public Health. 2017 May 23;14(6):
pubmed: 28545248
Int J Food Sci Nutr. 2018 Mar;69(2):125-143
pubmed: 28675945
Ecol Evol. 2017 Jul 07;7(16):6382-6389
pubmed: 28861241
Eur Heart J. 2018 Aug 7;39(30):2780-2792
pubmed: 29905796
Res Vet Sci. 2018 Oct;120:17-27
pubmed: 30170184
Front Pharmacol. 2018 Sep 21;9:1064
pubmed: 30298007
Front Microbiol. 2018 Nov 05;9:2651
pubmed: 30455677